Audiomedica.com
Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 8:52:00
- Mas informaciones
Informações:
Sinopsis
COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the second generation anaplastic lymphoma kinase (ALK) inhibitor ceritinib rather than chemotherapy in the phase 3 …161207-esmo-giorgio-scagliotti-ajo-production-master
